One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Asia-Pacific Genetic Testing Market

[ 英語タイトル ] Asia-Pacific Genetic Testing Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083610
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Asia Pacific
Report format : PDF
Sales price option (consumption tax not included)
Single User USD3750 / Question Form
5 User USD4250 / Question Form
Enterprise User USD7000 / Question Form
 - Abbott Laboratories
- Bio-Rad Laboratories Inc.
- Danaher Corporation (Cepheid)
- Genomic Health Inc.
- F. Hoffmann-La Roche Ltd
- Illumina Inc.
- Mapmygenome
- Myriad Genetics Inc.
- Qiagen NV
- Thermo Fisher Scientific Inc.

[Report Description]

The Asia-Pacific Genetic Testing market was expected to grow with a CAGR of 11.0%. Certain factors that are driving the market growth include a growing demand for personalized medicine and the increased application of genetic testing in oncology.

The FDA has approved several drugs for the treatment of lung cancer. Genetic discoveries over the past decade have transformed the way doctors treat and interpret this disease. Personalized medicine and genetic services play a vital role in wellness, prevention, and selection of cost-saving therapy.

The diagnostic and pharmaceuticals sector in the Asia-Pacific region has gained momentum, owing to speedy adoption and rising technological advancements. This has resulted in the adoption of personalized medicine across the region, including the creation of a pharmacogenomics research network, across the globe.

Key Market Trends

Diagnostic Testing is Expected to Hold its Highest Revenue Share in the Testing Type Segment

- By type, diagnostic testing is believed to have the largest market size. The is due to the detection of diseases and treatment at an early stage to minimize the severity of diseases, leading to a reduced mortality rate. Treatment at an early stage requires diagnostic testing and this is expected to increase the market demand over the forecast period.
- In recent years, China has been concentratring increasingly on genetic science, with several trials underway. The country is also quietly at work, building the world’s biggest DNA database. Thus, China is rapidly increasing the appetite for DNA-reading technology, which is helping companies that can help unravel the genetic code grow.
- DNA labs in India are ranked as India’s number one Genetic DNA Testing Laboratories. There are 3,000 sample collection centers and tie-ups with 500 hospitals across India. This network performs more than 5,000 tests per day. Hence, all the aforementioned factors are contributing to the growth of the market.

Competitive Landscape

The Asia-Pacific genetic testing market is highly competitive and consists of several major players. In terms of market share, a few major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new ingredients at lower prices. Companies like Abbott Laboratories Inc., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Genomic Health Inc., and Mapmygenome hold the substantial market share in the Asia-Pacific genetic testing market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Emphasis on Early Disease Detection and Prevention
4.2.2 Growing Demand for Personalized Medicine
4.2.3 Increasing Application of Genetic Testing in Oncology
4.3 Market Restraints
4.3.1 High Costs of Genetic Testing
4.3.2 Social and Ethical Implications of Genetic Testing
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Carrier Testing
5.1.2 Diagnostic Testing
5.1.3 Newborn Screening
5.1.4 Predictive and Presymptomatic Testing
5.1.5 Prenatal Testing
5.1.6 Other Types
5.2 By Disease
5.2.1 Alzheimer's Disease
5.2.2 Cancer
5.2.3 Cystic Fibrosis
5.2.4 Sickle Cell Anemia
5.2.5 Duchenne Muscular Dystrophy
5.2.6 Thalassemia
5.2.7 Huntington's Disease
5.2.8 Rare Diseases
5.2.9 Other Diseases
5.3 By Technology
5.3.1 Cytogenetic Testing
5.3.2 Biochemical Testing
5.3.3 Molecular Testing
5.4 Geography
5.4.1 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 Danaher Corporation (Cepheid)
6.1.4 Genomic Health Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Illumina Inc.
6.1.7 Mapmygenome
6.1.8 Myriad Genetics Inc.
6.1.9 Qiagen NV
6.1.10 Thermo Fisher Scientific Inc.




Recommended reports